Brought to you by 
Generex nets $10.55mm through registered direct offering
09 Jul 2009
Executive Summary
Generex Biotechnology (drug delivery technologies) has netted $10.55mm through the registered direct offering (RDO) of 17.2mm common shares at $0.64 (a 4% discount) to accredited investors. The backers also received five-year warrants to buy another 8.6mm shares at $0.76. Midtown Partners & Co. was the placement agent. The company will use the funds to gain regulatory approval for Generex Oral-lyn oral insulin spray in countries including the US, Canada, Mexico, and the EU. Last month the company netted $4.9mm through an RDO.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Generex nets $10.55mm through registered direct offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice